These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30379691)

  • 1. Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer.
    Nhean S; Bravo J; Sheehan NL; Walmsley S; Tilley D; Tseng AL
    AIDS; 2018 Nov; 32(17):2640-2642. PubMed ID: 30379691
    [No Abstract]   [Full Text] [Related]  

  • 2. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzalutamide (Xtandi) for prostate cancer.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient.
    Casserly EA; Rogers SE; Keisner SV
    J Oncol Pharm Pract; 2017 Jan; 23(1):68-70. PubMed ID: 26454199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Falsely Elevated Digoxin Levels in Patients on Enzalutamide.
    Kalra D; Tesfazghi M
    Circ Heart Fail; 2020 Jul; 13(7):e007008. PubMed ID: 32527146
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Miller M; Kunkler R
    Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int; 2017 Aug; 120(2):168-184. PubMed ID: 28719114
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer].
    Thelen P; Gschwend J; Wolff JM; Miller K
    Aktuelle Urol; 2016 Feb; 47(1):79-85. PubMed ID: 26814975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
    Tombal B; Borre M; Rathenborg P; Werbrouck P; Van Poppel H; Heidenreich A; Iversen P; Braeckman J; Heracek J; Baskin-Bey E; Ouatas T; Perabo F; Phung D; Hirmand M; Smith MR
    Lancet Oncol; 2014 May; 15(6):592-600. PubMed ID: 24739897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer: enzalutamide impresses in European studies.
    Payton S
    Nat Rev Urol; 2014 May; 11(5):243. PubMed ID: 24776976
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzalutamide and sleep apnea: an emerging central nervous system side-effect?
    Labrize F; Cany L; Massard C; Loriot Y; Sargos P; Gross-Goupil M; Roubaud G
    Ann Oncol; 2016 Jan; 27(1):206. PubMed ID: 26445811
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
    Tombal B; Borre M; Rathenborg P; Werbrouck P; Van Poppel H; Heidenreich A; Iversen P; Braeckman J; Heracek J; Baron B; Krivoshik A; Hirmand M; Smith MR
    J Urol; 2018 Feb; 199(2):459-464. PubMed ID: 28867562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-androgen monotherapy for metastatic prostate cancer.
    Attard G
    Lancet Oncol; 2014 May; 15(6):543-4. PubMed ID: 24739898
    [No Abstract]   [Full Text] [Related]  

  • 17. Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer.
    Westdorp H; Kuip EJM; van Oort IM; Kramers C; Gerritsen WR; Vissers KCP
    J Pain Symptom Manage; 2018 Apr; 55(4):e6-e8. PubMed ID: 29175468
    [No Abstract]   [Full Text] [Related]  

  • 18. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

  • 19. Age Adjusted Charlson Comorbidity Index Strongly Influences Survival, Irrespective of Performance Status and Age, in Patients With Advanced Prostatic Cancer Treated With Enzalutamide.
    VAN Halteren HK; Vreugdenhil G
    Anticancer Res; 2019 Feb; 39(2):863-866. PubMed ID: 30711968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
    Cicero G; DE Luca R; Dorangricchia P; Dieli F
    Anticancer Res; 2017 Mar; 37(3):1475-1480. PubMed ID: 28314320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.